Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Coronary Artery Disease (ADVANCE-PCI)

This study has been terminated.
(Funding withdrawn)
Sponsor:
Collaborator:
Royal College of Surgeons, Ireland
Information provided by (Responsible Party):
Professor Noel Caplice, University College Cork
ClinicalTrials.gov Identifier:
NCT00905294
First received: May 19, 2009
Last updated: June 17, 2013
Last verified: June 2013

May 19, 2009
June 17, 2013
August 2009
August 2010   (final data collection date for primary outcome measure)
relationships between ADAMTS-13 activity, von Willebrand factor antigen and platelet-monocyte aggregates levels [ Time Frame: change from baseline to after percutaneous coronary intervention ] [ Designated as safety issue: No ]
Assess the relationships between ADAMTS-13 activity, von Willebrand factor antigen and platelet-monocyte aggregates levels in subjects with coronary artery disease prior to and after undergoing PCI in this exploratory study
Not Provided
Complete list of historical versions of study NCT00905294 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Coronary Artery Disease
ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Patients Undergoing Percutaneous Coronary Intervention

The purpose of this research is to determine the relationship between proteins and enzymes in the blood and how they work with platelets to form blood clots in patients with coronary artery disease. The investigators hypothesize that the relationship between these factors could potentially be useful in identifying patients at higher risk for heart attacks.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

serum, plasma

Probability Sample

Patients with coronary artery disease undergoing percutaneous coronary intervention

Coronary Artery Disease
Other: Blood draws
Observational: blood draws only
coronary artery disease
Subjects with coronary artery disease undergoing percutaneous coronary intervention
Intervention: Other: Blood draws
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
11
August 2010
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Admission to hospital with suspected index event of Non-ST-Elevation Myocardial Infarction (NSTEMI), Unstable Angina (UA) or Stable Angina (SA)
  • Planned percutaneous coronary intervention during admission

Exclusion Criteria:

  • Recent history (< 6 months) of an acute coronary syndrome (other than current admission) or stroke
  • Recent history (< 6 months) of major surgery, trauma or thromboembolic event
  • Percutaneous coronary or peripheral intervention or any stent placement performed within the past 6 months
  • Current evidence of infection
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Ireland
 
NCT00905294
INFACTs 2009-001
No
Professor Noel Caplice, University College Cork
University College Cork
Royal College of Surgeons, Ireland
Principal Investigator: Noel M. Caplice, M.D, Ph.D. University College Cork, Ireland
Study Director: Dermot Kenny, M.D. Royal College Surgeons in Ireland
Study Director: David Foley, M.B. Beaumont Hospital, Dublin, Ireland
University College Cork
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP